Status:
TERMINATED
Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc )
Lead Sponsor:
Merit Medical Systems, Inc.
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
This registry is intended to demonstrate the utility of SCOUT® in the Canadian public and US healthcare systems with fixed resources and a conservative approach to patient and clinician exposure to ha...
Detailed Description
This registry is intended to demonstrate the utility of SCOUT® in the Canadian public and US healthcare systems with fixed resources and a conservative approach to patient and clinician exposure to ha...
Eligibility Criteria
Inclusion
- Woman \>18 years and \< 80 years of age;
- Classified as Breast Imaging Reporting and Data System (BI-RADS) 4C or 5;
- Lesion depth is \< 6 cm from skin surface;
- Non-palpable lesions;
- Informed consent obtained.
Exclusion
- Multicentric breast cancer;
- Pregnant or lactating;
- Known or suspected nickel-titanium allergy.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2024
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT04815291
Start Date
April 1 2022
End Date
January 15 2024
Last Update
May 21 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
2
St. Sacrement
Québec, Canada